Publications by authors named "P Schino"
Article Synopsis
- * The study involved 42 patients with varying severities of pneumonia, assessing their lung health through inflammation indices, CT scans, and respiratory tests at multiple follow-up intervals (70±30 days, 6, 12, 24, and 36 months post-discharge).
- * Findings revealed that 83.3% of patients retained lung damage by the 36-month mark, especially those with severe pneumonia, indicating lasting effects on respiratory function and a correlation between pneumonia severity and lung lesion persistence.
Purpose: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching biologic treatment is a strategy adopted to optimize asthma control when patients show partial or no response to previous biologics.
Patients And Methods: ANANKE is a retrospective, multicenter Italian study (NCT04272463). Here, we outline the characteristics and long-term clinical outcomes in naïve-to-biologics and biologics-experienced patients treated with benralizumab for up to 96 weeks.
Article Synopsis
- The TRITRIAL study evaluated the fixed combination of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) in patients with chronic obstructive pulmonary disease (COPD), focusing on patient-reported outcomes over 12 months.
- In a multicenter, prospective observational study with 655 patients, significant improvements were observed in health status (CAT scores), adherence to medication, quality of life, and sleep quality.
- The findings suggest that BDP/FF/G not only enhances the management of moderate-severe COPD but also improves overall patient well-being and reduces exacerbation rates.
Background: The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects. Here we present novel data from the ANANKE study in which a large cohort of SEA patients was treated for up to 96 weeks.
Methods: ANANKE (NCT04272463) is an observational retrospective Italian study investigating the key characteristics of SEA patients (collected during the 12 months prior to benralizumab initiation) and the clinical outcomes during benralizumab treatment (annual exacerbation rate [AER], lung function, asthma control, OCS use, healthcare resource utilization).
Purpose: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm are poorly represented. This post hoc analysis from the Italian study ANANKE aims to define the clinical features and corroborate the efficacy of benralizumab in real world in the BEC 300-450 cells/mm subset of patients.
View Article and Find Full Text PDF